Nuveen Asset Management LLC Raises Stock Holdings in Bruker Co. (NASDAQ:BRKR)

Nuveen Asset Management LLC raised its stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 35.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,217,940 shares of the medical research company's stock after buying an additional 318,630 shares during the period. Nuveen Asset Management LLC owned about 0.80% of Bruker worth $71,396,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. raised its holdings in shares of Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after purchasing an additional 248 shares during the last quarter. Quadrant Capital Group LLC increased its position in Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Bruker by 41.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after purchasing an additional 390 shares during the period. Parvin Asset Management LLC acquired a new position in shares of Bruker during the fourth quarter valued at about $112,000. Finally, GeoWealth Management LLC lifted its holdings in Bruker by 1,093.9% in the 4th quarter. GeoWealth Management LLC now owns 2,137 shares of the medical research company's stock valued at $125,000 after purchasing an additional 1,958 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Stock Performance

NASDAQ BRKR traded down $1.74 during trading hours on Wednesday, hitting $36.45. The company had a trading volume of 2,464,261 shares, compared to its average volume of 1,611,229. The firm has a market cap of $5.52 billion, a P/E ratio of 47.96, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $78.94. The business has a fifty day simple moving average of $40.05 and a 200-day simple moving average of $50.17.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. The company had revenue of $801.40 million for the quarter, compared to analyst estimates of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Bruker's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.53 EPS. Equities analysts predict that Bruker Co. will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.55%. Bruker's payout ratio is 38.46%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on BRKR shares. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a report on Monday, February 24th. Wells Fargo & Company lowered their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. UBS Group reduced their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. The Goldman Sachs Group decreased their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Finally, Citigroup cut their price objective on Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $60.10.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.